Leading Experts In The Field Of AML Treatment And Bone Marrow Transplant To Discuss Available Treatment Options And Potential New Opportunities Including Actinium Pharmaceuticals, Inc. (ATNM.OB)’s Iomab™-B At NY Biotechnology Industry Organization (BIO) Conference
5/13/2014 7:26:14 AM
Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced participation in an upcoming panel discussion highlighting the potential role of Actinium’s products in the treatment of older refractory/relapsed acute myeloid leukemia (AML) patients.
Help employers find you! Check out all the jobs and post your resume.
comments powered by